Abstract
Abstract: :
Purpose: In our previous study improvement of visual functions (visual field mean defect, foveal sensitivity, visual acuity) were observed in early AMD after 1 year of treatment with a combination of highly concentrated n–3 fatty acids (DHA+EPA), coenzyme Q10 and acetyl–L–carnitine. The aim of the present study was to examine whether these changes were associated with improvement of fundus alterations. Methods: 106 patients aged between 55 and 70 with early AMD were enrolled in randomized a double blind, placebo controlled study. They were treated either with PhototropTM capsules (treated group), or with soy oil (placebo group). Fundus photographs were taken at the screening, after 6 and 12 months and they were evaluated by the criteria of the International Classification and Grading System for AMD. Results:When the most severe eyes were evaluated: in the placebo group 15 eyes improved, 19 eyes unchanged, and 16 eyes worsened, while in the treated group 21 eyes improved, 18 eyes unchanged, and 8 eyes worsened. The differences compared to the placebo group were +40%, –5% and –50%, respectively. When both affected eyes were studied: in the placebo group 28 eyes improved, 40 eyes unchanged and 24 eyes worsened, while in the treated group 45 eyes improved, 36 eyes unchanged and 10 eyes worsened. The differences compared to the placebo group were +61%, –12%, and –58%, respectively. Conclusions: In addition to the previously described improvement in visual functions, fundus alterations characteristic for early AMD also showed significant improvement in patient taking a combination of n–3 fatty acid, coenzyme Q10 and acetyl–L–carnitine compared to the placebo group.
Keywords: age–related macular degeneration • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • pharmacology